Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 98.00 [1][5] Core Views - The company is expected to see growth in 2026 driven by its "all demographics + all price points + globalization" strategy, with new product lines such as building cars and international expansion contributing significantly [2][3] - Despite a weaker performance in traditional toy segments in 2025, new business lines like the 9.9 yuan Starry Edition and adult-oriented products are anticipated to boost revenue in the second half of 2025 and continue into 2026 [2] - The company has expanded its IP matrix, increasing the number of commercialized IPs from 14 in 2024 to 24 in 2025, with a total of approximately 63 IPs available for future development [2] - The introduction of new product categories, particularly building cars, is expected to contribute additional revenue in 2026, with the global vehicle toy market projected to reach RMB 102.8 billion [4] Summary by Sections Revenue and Profit Forecast - The adjusted profit forecast for 2025-2027 is projected at RMB 6.50 billion, RMB 8.71 billion, and RMB 11.60 billion respectively, with adjusted EPS of RMB 2.61, RMB 3.50, and RMB 4.65 [5][11] - Revenue is expected to grow significantly, with estimates of RMB 2.90 billion in 2025 and RMB 3.77 billion in 2026, reflecting year-on-year growth rates of 29.42% and 30.08% respectively [11][19] International Expansion - The company has made significant strides in its global strategy, achieving overseas revenue of RMB 1.11 billion in the first half of 2025, a year-on-year increase of 899%, with overseas revenue accounting for 8.3% of total revenue [3] - The company has showcased its products at international toy fairs in various countries, enhancing its global presence and brand recognition [3] Product Development - The company has accelerated its product launch schedule, with over 900 new SKUs introduced in 2025, particularly in the fourth quarter, which is expected to positively impact revenue in early 2026 [2] - The new building car products launched in November 2025 are expected to leverage high-density materials and innovative designs, enhancing user experience and driving sales growth [4]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 8.00 [1][9]. Core Insights - The company has demonstrated robust growth in retail sales, with both the main brand and children's clothing achieving approximately 10% year-on-year growth in 4Q25, continuing a steady growth trend despite high base effects [1][11]. - E-commerce sales recorded a high double-digit growth in 4Q25, indicating strong performance in online channels [7][11]. - The company is enhancing its brand power through innovative products and marketing strategies, including the introduction of "super stores" to upgrade channel efficiency and expand international presence [5][11]. Summary by Sections Operational Performance - In 4Q25, the main brand and children's clothing retail sales both achieved approximately 10% year-on-year growth, maintaining a steady growth trend [1][11]. - The e-commerce platform saw overall sales achieve high double-digit year-on-year growth, continuing a solid performance [7][11]. Product and Marketing Strategy - The company launched new products in various categories, including running, basketball, and outdoor gear, which have received significant market attention [6]. - The introduction of "super stores" is expected to enhance customer acquisition and sales efficiency, with a notable increase in new customer ratios [6]. Financial Projections - Revenue is projected to grow from RMB 10,074 million in 2024 to RMB 14,019 million by 2027, with a compound annual growth rate (CAGR) of approximately 10.30% [4]. - Net profit is expected to increase from RMB 1,149 million in 2024 to RMB 1,655 million by 2027, reflecting a steady growth trajectory [4]. Valuation Metrics - The company is assigned a target PE of 10.1x for 2026, with a target price of HKD 8.00, reflecting a discount compared to comparable companies due to its current brand scale and market share [9][13].

Investment Rating - The report maintains a "Strong Buy" rating for JD Group with a target price range of HKD 125 to 150, while the current stock price is HKD 117.4 [2][5]. Core Insights - JD Group's total revenue is expected to see a slight year-on-year increase in Q4 2025, with a projected Non-GAAP net profit of approximately 480 million yuan [1][5]. - The report highlights that the decline in revenue growth for the electric category is due to the reduction of national subsidies and a high comparative base from the previous year, while daily necessities and third-party (3P) revenues are expected to maintain double-digit growth [1][5]. - The report expresses a long-term positive outlook on the company's growth resilience under its self-operated model and strong supply chain bargaining power, which is expected to enhance profit margins [1][5]. Financial Data and Valuation - For the fiscal years 2023 to 2027, the projected main revenue (in million yuan) is as follows: 1,084,662 (2023), 1,158,819 (2024), 1,305,167 (2025E), 1,361,675 (2026E), and 1,419,895 (2027E), with year-on-year growth rates of 4%, 7%, 13%, 4%, and 4% respectively [2][6]. - The Non-GAAP net profit projections are: 35,200 (2023), 47,827 (2024), 26,428 (2025E), 32,720 (2026E), and 50,951 (2027E), with significant fluctuations in growth rates [2][6]. - The report indicates a P/E ratio forecast of 8.7 (2023), 6.4 (2024), 11.6 (2025E), 9.4 (2026E), and 6.0 (2027E) [2][9]. Stock Performance - The stock has shown an absolute performance of 9.1% over the past month, 17.6% over six months, and 20.0% over the past year [4]. - Relative performance indicates a 6.0% outperformance over one month, 2.4% over six months, but a 9.8% underperformance over the past year [4]. Business Segment Insights - The report notes that the new business segment is expected to reduce losses in Q4, with improvements in delivery volume and user experience (UE) for the food delivery service [1][5]. - The report anticipates that the food delivery business will continue to improve in 2026, with a focus on enhancing user experience [1][5]. Shareholder Information - The total share capital is 3,188 million shares, with 2,865 million shares listed in Hong Kong [3]. - The major shareholder, Max Smart Limited, holds a 9.6007% stake in the company [3]. Financial Ratios - The report provides key financial ratios, including a return on equity (ROE) of 17.8% and a debt-to-asset ratio of 57.3% [3][9]. - The projected earnings per share (EPS) for the years 2023 to 2027 are 8.34, 14.27, 5.85, 9.26, and 14.87 respectively [2][9].

研究报告 Research Report 14 Jan 2026 首次覆盖：重组胶原蛋白领军者，2026 战略转型开启品牌化新篇章 Recombinant Collagen Leader: 2026 Strategy Ushers in Brand New Era: Initiation [Table_yemei1] 观点聚焦 Investment Focus [Table_Info] 首次覆盖优于大市 Initiate with OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$35.74 目标价 HK$43.60 HTI ESG 3.1-3.9-4.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$38.27bn / US$4.91bn 日交易额 (3 个月均值) US$58.76mn 发行股票数目 1,071mn 自由流通股 (%) 45% 1 年股价最高最低值 HK$84.90-HK$33.28 注：现价 HK$35.74 为 2026 年 01 月 13 日收盘价 资料来源： Factset ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance in the near term [7][19]. Core Insights - The company has demonstrated strong revenue growth, with a projected increase in operating income from 84.23 billion RMB in FY2023 to 130.8 billion RMB by FY2027, reflecting a compound annual growth rate (CAGR) of approximately 8% [7][19]. - The net profit attributable to shareholders is expected to grow from 9.6 billion RMB in FY2023 to 15.1 billion RMB in FY2027, with a steady growth trajectory [7][19]. - The company has successfully expanded its "super premium" store concept, with 126 stores opened by the end of 2025, exceeding expectations and contributing to its revenue growth [7][19]. - The company has maintained a stable discount rate of 7-7.1, indicating effective inventory management and pricing strategy [7][19]. - The introduction of new product lines and strategic marketing partnerships has enhanced brand visibility and sales performance, particularly in the running and basketball segments [7][19]. Financial Data and Profit Forecast - Revenue projections for FY2023 to FY2027 are as follows: 84.23 billion RMB, 100.7 billion RMB, 111.8 billion RMB, 121.4 billion RMB, and 130.8 billion RMB, respectively, with corresponding growth rates of 21%, 20%, 11%, 9%, and 8% [7][19]. - Net profit forecasts for the same period are 9.6 billion RMB, 11.5 billion RMB, 12.6 billion RMB, 13.9 billion RMB, and 15.1 billion RMB, with growth rates of 29%, 20%, 10%, 10%, and 9% [7][19]. - The company's gross margin is projected to improve slightly from 41.1% in FY2023 to 41.9% in FY2027, indicating efficient cost management [7][19].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has demonstrated strong growth momentum with double-digit revenue growth, particularly in the fourth quarter of 2025, where both adult and children's apparel retail sales increased by approximately 10% year-on-year [7] - The expansion of super stores has exceeded expectations, with a total of 126 super stores opened by the end of 2025, including 21 children's clothing stores, contributing significantly to offline growth [7] - The company maintains a healthy inventory level with a stable discount rate, indicating robust operational performance [7] - Product innovation and enhanced marketing strategies are driving brand strength, with new product launches in running and basketball categories [7] - The company is also expanding its outdoor brand "One Way," which is expected to capitalize on the growing outdoor trend [7] - The financial forecasts indicate a steady increase in revenue and net profit, with projected net profits of 12.6 billion, 13.9 billion, and 15.1 billion RMB for FY2025, FY2026, and FY2027 respectively [6][18] Financial Data and Profit Forecast - Revenue projections are as follows: - FY2023: 84.23 billion RMB - FY2024: 100.7 billion RMB - FY2025E: 111.8 billion RMB - FY2026E: 121.4 billion RMB - FY2027E: 130.8 billion RMB - Net profit projections are as follows: - FY2023: 9.6 billion RMB - FY2024: 11.5 billion RMB - FY2025E: 12.6 billion RMB - FY2026E: 13.9 billion RMB - FY2027E: 15.1 billion RMB - The company’s gross margin is expected to improve slightly from 41.1% in FY2023 to 41.9% in FY2027 [6][18]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for its stock performance in the next 12 months [2]. Core Insights - The company has entered a value realization phase with its AI pharmaceutical platform, highlighted by the clinical trial approval of its drug RTX-117 for Charcot-Marie-Tooth disease, marking a significant milestone in its drug development pipeline [6]. - The innovative approach of RTX-117 targets the key mechanisms of the disease, demonstrating effective restoration of motor function in preclinical studies, thus validating the company's AI-driven drug development capabilities [6]. - The company has established a robust business model that integrates AI technology with a flexible commercial strategy, allowing for rapid drug development and a diversified revenue stream from collaborations with major pharmaceutical companies [6]. - The financial projections indicate substantial revenue growth, with expected revenues of RMB 785 million in 2025 and RMB 1.485 billion in 2027, alongside a path to profitability by 2027 [2][7]. Financial Projections - Revenue is projected to grow from RMB 266 million in 2024 to RMB 1.485 billion in 2027, reflecting a compound annual growth rate (CAGR) of approximately 36.6% [2][7]. - The net profit attributable to shareholders is expected to improve from a loss of RMB 1.517 billion in 2024 to a profit of RMB 92 million in 2027, indicating a significant turnaround [2][7]. - The earnings per share (EPS) is forecasted to transition from -0.35 RMB in 2024 to 0.02 RMB in 2027, suggesting a positive shift towards profitability [2][7].

Investment Rating - The report maintains a "Buy-B" rating for the company 361 Degrees (01361.HK) [1][6] Core Insights - The company reported a healthy growth in retail sales, with a 10% year-on-year increase in offline retail sales for both the main brand and children's clothing in Q4 2025. The e-commerce platform saw a high double-digit growth in retail sales [2][4] - The company has successfully expanded its premium store count to 126 by the end of 2025, with the first overseas premium store opening in Cambodia, indicating a significant step in international market expansion [5][6] - The average retail discount for new products in Q4 2025 was approximately 7-7.1 folds, and the inventory turnover ratio remained stable at 4.5-5 months [5] Financial Performance and Projections - The company’s revenue for 2025 is projected to be 11,367 million, with a year-on-year growth of 12.8%. The net profit is expected to reach 1,285 million, reflecting a growth of 11.9% [8][12] - Earnings per share (EPS) for 2025-2027 are forecasted at 0.62, 0.69, and 0.76 respectively, with corresponding price-to-earnings (P/E) ratios of approximately 8.4, 7.5, and 6.9 [6][12] - The gross margin is expected to remain stable at around 41.5% for the forecasted years [12]

Investment Rating - The investment rating for Alibaba-W (09988.HK) is "Outperform" [1][6][4] Core Views - The report anticipates a revenue growth of 2% year-on-year for 3QFY26, with an expected revenue of 285.8 billion yuan. The adjusted EBITA margin is projected to be 11.7%, reflecting a decline of 7.8 percentage points year-on-year [3][5] - The international digital commerce group and cloud intelligence revenue are expected to grow by 8% and 35% year-on-year, respectively, indicating continued acceleration in cloud revenue growth [3][10] - The report highlights the ongoing investment in AI and model training, which is expected to impact profitability in the short term but may enhance competitive positioning in the long run [11][22] Summary by Sections Financial Performance - For 3QFY26, Alibaba is projected to achieve a revenue of 285.8 billion yuan, with a year-on-year increase of 2%. The adjusted EBITA is expected to be 33.5 billion yuan, down 39% year-on-year [3][5] - The adjusted EBITA margin is forecasted at 11.7%, a decrease of 7.8 percentage points compared to the previous year [5][3] Cloud Business - The cloud segment is expected to see a revenue increase of 35% year-on-year in FY26Q3, with a stable EBITA margin. The Qwen model is anticipated to enhance the company's market share in overseas markets [10][11] E-commerce Performance - The e-commerce group's GMV is expected to grow by 3% year-on-year in FY26Q3, influenced by a weak retail environment. The report notes that the monetization rate is expected to align closely with GMV growth [19][21] - Instant retail is projected to incur losses of approximately 20-25 billion yuan, with a focus on maintaining market share through increased investment [21][22] Financial Forecasts - Revenue forecasts for FY2026-FY2028 have been slightly adjusted to 1,030.7 billion, 1,149.4 billion, and 1,275.1 billion yuan, reflecting a decrease of 1.5%, 2.8%, and 1.4%, respectively, due to a soft consumer environment [4][23] - Adjusted net profit forecasts for FY2026-FY2028 are revised to 101.6 billion, 135.4 billion, and 165.5 billion yuan, with adjustments of -9.1%, -6.6%, and -3.7% respectively [4][23]

Investment Rating - The report indicates a positive outlook for WuXi Biologics, suggesting that the company will outperform its peers in the biopharmaceutical CDMO sector in 2026 [5]. Core Insights - WuXi Biologics is expected to experience a reacceleration in growth in 2026, driven by three main catalysts: the growth momentum from dual/multi-antibody projects, a strong project intake in 2025 with a net addition of 128 projects, and a reduction in valuation pressure from geopolitical factors [5][8]. - The non-XDC business of WuXi Biologics is anticipated to accelerate in 2026, contrary to market expectations, returning the company to a multi-engine growth trajectory [6]. - The company’s dual/multi-antibody projects are projected to be a significant growth driver, with a 30% year-on-year increase in project numbers for 2025, outpacing the overall company growth rate of 16% [7]. Summary by Sections Company Overview - WuXi Biologics is a leading global contract research, development, and manufacturing organization (CRDMO) that provides end-to-end solutions to help partners develop biopharmaceuticals from concept to commercialization [10]. Financial Performance - As of January 9, 2026, the stock price is HKD 37.06, with a market capitalization of USD 19.65 billion. The average daily trading volume over the past three months is USD 138.43 million [13]. - The revenue breakdown shows that biopharmaceuticals account for 88.8% of total revenue, while WuXi XDC contributes 11.2% [11]. Growth Drivers - The report highlights that the strong project intake in 2025, with 128 new projects, sets a solid foundation for faster growth in 2026 compared to 2025 [5][8]. - The profitability outlook is favorable due to the optimization of the project structure towards complex dual/multi-antibody projects, which is expected to enhance profit margins [7].